IMUX - upcoming catalysts - insidersThis is not a financial advice!
I see a test of 3, if we break we might seeing a gap fill.
Most info on the chart.
Trade carefully!
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.0350 USD
−100.51 M USD
0.00 USD
92.92 M
About Immunic, Inc.
Sector
Industry
CEO
Daniel Vitt
Website
Headquarters
New York
Founded
2003
FIGI
BBG001M75SX4
Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm’s products include IMU-838, IMU-935, and IMU-856. The company was founded in May 2003 and is headquartered in New York, NY.
IMUX monitoringIMUX is trading with high trading volume.
there is a divergence in the RSI indicator.
5K - 10K Challenge (Trade 003)OK traders, this is not trading advice.
I am attempting to turn 5K (approx) into 10k over the rest of the year for a bit of fun and hopefully a bit of profit!!
This is trade number 3 today, IMUX is a stock I am quite familiar with, I've lost lots of money with this stock ha ha!
IMUX has a trading r
Immunic impressive pipeline and ready to go 80% this yearNot much I can say about Immunic that you probably don't already know if you're looking at this, they have dropped nicely lately, this is the bottom it looks like and this ompany has a very impressive pipeline, been waiting a long time to get back into this and I consider this a sale price. At worst
IMUX heading higherIMUX has been trading in the channel for over 6 months.
Now it seems it is trying to break it.
If it stands the support at 20.20 (used to be resistance), it may look like a good BUY signal.
Alternatively, can try to wait if it drops back to the support at 15.00.
I think I will give it a try now.
IMUX, price may drop as it breaks higher Bollinger Band on Feb 8This price move could be a signal that IMUX may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options. Tickeron's A.I.dvisor backtested 41 similar cases where IMUX's price broke its higher Bollinger Band,
IMUXIMUX, it seems to me in an accumulation phase, phase trapped in a triangle, the eventual breakdown of the descending train will give us confirmation that the lateral phase is over
IMUX, Stochastic Oscillator left the oversold zone on January 06This is a signal that IMUX's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options. Tickeron's A.I.dvisor identified 68 similar cases where IMUX's stochastic oscillator exited the oversold zone, and 59 of them led to successful outcomes. Odds of Succes
IMUX to gain 20%+IMUX has without doubt one of the most impressive pipelines I have seen in biotech, the potential here is just massive. I bought stock and I am not selling, this will be good news after good news after more good news.
I listened to hour long call with CEO and some of the highlights are as follows:
Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838Immunic, Inc. Reports Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis
Study Meets Primary and Key Secondary Endpoints with High Statistical Significance
Statistically Significant Reduction of 62% and 70%
Data Supports Previousl
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of IMUX is 1.1000 USD — it has increased by 1.10% in the past 24 hours. Watch Immunic, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Immunic, Inc. stocks are traded under the ticker IMUX.
IMUX stock has risen by 9.89% compared to the previous week, the month change is a −11.50% fall, over the last year Immunic, Inc. has showed a −11.29% decrease.
We've gathered analysts' opinions on Immunic, Inc. future price: according to them, IMUX price has a max estimate of 28.00 USD and a min estimate of 5.00 USD. Watch IMUX chart and read a more detailed Immunic, Inc. stock forecast: see what analysts think of Immunic, Inc. and suggest that you do with its stocks.
IMUX reached its all-time high on Jun 13, 2014 with the price of 1,408.0000 USD, and its all-time low was 0.8319 USD and was reached on Apr 9, 2025. View more price dynamics on IMUX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
IMUX stock is 13.20% volatile and has beta coefficient of 1.11. Track Immunic, Inc. stock price on the chart and check out the list of the most volatile stocks — is Immunic, Inc. there?
Today Immunic, Inc. has the market capitalization of 95.82 M, it has increased by 8.86% over the last week.
Yes, you can track Immunic, Inc. financials in yearly and quarterly reports right on TradingView.
Immunic, Inc. is going to release the next earnings report on May 8, 2025. Keep track of upcoming events with our Earnings Calendar.
IMUX earnings for the last quarter are −0.25 USD per share, whereas the estimation was −0.23 USD resulting in a −6.38% surprise. The estimated earnings for the next quarter are −0.24 USD per share. See more details about Immunic, Inc. earnings.
Immunic, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
IMUX net income for the last quarter is −25.18 M USD, while the quarter before that showed −24.37 M USD of net income which accounts for −3.31% change. Track more Immunic, Inc. financial stats to get the full picture.
No, IMUX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 23, 2025, the company has 91 employees. See our rating of the largest employees — is Immunic, Inc. on this list?
Like other stocks, IMUX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Immunic, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Immunic, Inc. technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Immunic, Inc. stock shows the sell signal. See more of Immunic, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.